CD - Hep B-part 2, Hep C Flashcards by S R

is there a treatment for Hep B (1)

1- no cure

How well did you know this?

Not at all

Perfectly

are there medications that can reduce morbidity from hep B (1)

1- yes - antivirals and immunomodulators can reduce viral replication and thus reduce liver damage in chronic infection

How well did you know this?

Not at all

Perfectly

what is the schedule for hep B vaccine (1)

1- not age-dependent per se:
3 doses at 0, 1 and 6 months (month 0 = first dose)

How well did you know this?

Not at all

Perfectly

are booster doses required for hep B vaccine in immunocompetent people (1)

1- no

How well did you know this?

Not at all

Perfectly

are booster doses required for hep B vaccine in those at high risk of HBV infection/complications (1)

1- high-risk people who do not develop anti-HBs titre of at least 10 IU/L after the
initial HB vaccine series should receive a second
HBV vaccine series

How well did you know this?

Not at all

Perfectly

what is the effectiveness of hep B vaccine (1)

1- 95-100% effective in preventing chronic infection

How well did you know this?

Not at all

Perfectly

how long is the hep B vaccine effective for (1)

1- protection against chronic disease lasts for at least 30 years following immunization - I.e. protection can last for decades

How well did you know this?

Not at all

Perfectly

Within what timeframe do you get post-immunization serologic testing (anti-HBs titre) (1)

1- within 1-6 months after completion of vaccine series, for recommended groups

How well did you know this?

Not at all

Perfectly

what are the groups recommended to get post-imm serologic testing (anti-HBs) titre -

‘medical condition’ - 5
‘contacts’ - 2
‘occupational’ - 1

(8)

1- immunocompromised people
2- those on dialysis or with chronic renal disease
3- advanced liver disease
4- solid organ transplant candidates and recipients
5- pregnant women at high risk of HBV infection
6- those with potential exposure (percutaneous, mucosal)
7- sexual and household contacts of acute cases and chronic carriers of HBV
8- workers who need confirmation of immunity due to potential for occupational exposure

How well did you know this?

Not at all

Perfectly

in individuals who meet the groups recommended to get HBV post-imm serology, how long should titres be delayed from being collected if the person received HBIg PEP (1)

1- anti-HBs titre should be delayed for 6 months post HBIg PEP

How well did you know this?

Not at all

Perfectly

what would an infant HBV vaccination program be most effective at reducing (1)

1- number of chronic carriers

How well did you know this?

Not at all

Perfectly

why would an infant HBV vaccination program be effective at reducing the number of chronic carriers (2)

1- 90% of infants infected with HBV go on to develop cirrhosis i.e. chronic infection
2- despite targeted imms for infants born to HBV+ moms, some infants are missed and acquire HBV - universal infant program would prevent these cases

How well did you know this?

Not at all

Perfectly

what would an adolescent HBV vaccination program be most effective at reducing (1)

1- number of acute infections

How well did you know this?

Not at all

Perfectly

why would an adolescent HBV vaccination program be effective at reducing the number of acute infections (2)

1- most acute HBV cases occur in adolescents/adults
2- there often is a rapid drop in antibodies for the first year, so adolescents will have maximum protection at time of greatest risk if vaccine given in adolescence

How well did you know this?

Not at all

Perfectly

what is an anamnestic reaction (1)

1- renewed rapid production of an antibody following second or later contact with the original provoking antigen/related antigens

How well did you know this?

Not at all

Perfectly

what is a caveat with an adolescent HBV vaccine program that is more in favour of an infant program (1)

1- around 90% of 18-year olds will mount an anamnestic response after a primary infant series…so it might make more sense to do an infant program to hit both chronic carrier/acute infection numbers

How well did you know this?

Not at all

Perfectly

in general, what is the landscape in Canada of HBV vaccination programs in terms of routine infant vs. adolescent programs (1a) and for high-risk infants (1b)

1a- inconsistent across the country - roughly half the provinces have infant program, the other half have adolescent program
1b- all provinces have programs for high-risk infants

How well did you know this?

Not at all

Perfectly

HBV case management: what education on safe sex should you provide (1)

1- acute cases should abstain from sex OR practice safer sex until contacts have been appropriately screened and immunized

How well did you know this?

Not at all

Perfectly

HBV case management: what kind of clinical mgmt do cases need (2)

1- test for other STIs and HIV
2- carriers to be linked with appropriate other services based on morbidity

HBV case management: what is guidance re: blood donation for cases (1)

1- acute cases and carriers of HBV cannot donate blood - cannot donate if you’ve ever tested positive for HBV

HBV contact mgmt: who would be considered HBV contact (4)

1- household contact of acute case/carrier
2- sexual contact of case/carrier
3- percutaneous or mucosal exposure to blood/bodily fluids potentially containing HBV (e.g. razor, toothbrush)
4- infants born to HBV+ mother

HBV contact mgmt: what is PEP for non-sexual household contacts (1)

1-
HBV vaccine ONLY (no HBIg)

HBV contact mgmt: what is the timeline for offering immunoprophylaxis as part of PEP (2)

1-
within 7 days of a percutaneous/mucosal exposure
2-
within 14 days of sexual exposure

HBV contact mgmt: what is the timeline for offering immunoglobulin as part of PEP (1)

1-
within 48h of exposure but up to 7 days of perc/mucosal exposure, or up to 14 days of sexual exposure

HBV contact mgmt: what is PEP for sexual household contacts (2)

1- HBV vaccine 2- HBIg

HBV contact mgmt: what is PEP for percutaneous/mucosal exposure (2)

1- HBV vaccine 2- HBIg

HBV contact mgmt: what is PEP for infants born to HBV+ mother (2)

1- HBV vaccine 2- HBIg

what is the agent for hepatitis C (1)

1- hepatitis C virus (HCV)

what are risk factors for hep C virus acquisition - SDoH - 5 Nosocomial/medical condition - 3 Lifestyle/travel - 3 (11)

1- current/hx of IVDU 2- hx of incarceration 3- those who are marginally housed 4- high-risk sexual behaviours with HCV+ person 5- intranasal/inhalational drug use with HCV+ person 6- received healthcare when no universal precautions (e.g. non-sterile equipment) 7- received blood products/transfusion, organ transplant before 1992 in Canada 8- hemodialysis 9- born, travelled or resided in HCV-endemic countries 10- those who have had needle-stick injuries 11- tattooing/piercing/sharing sharp (personal hygiene) instruments with HCV+ person

what is the reservoir for HCV (1)

1- humans

what is the mode of transmission for HCV (1, and 2 less likely)

1- blood-borne (e.g. needles, transfusion) 2- sexual/vertical transmission less likely

what is the incubation period for HCV - range (1)

1- range: 2 weeks to 6 months

what is the period of communicability for HCV (1)

1- 1-2 weeks after exposure, may persist indefinitely in chronic carriers

can HCV cases be asymptomatic (1)

1- YES - 20-30% of cases are asymptomatic

if symptomatic, what is the clinical presentation of HCV infection - JAFNA (5)

SLOW, GRADUAL ONSET OF 1- jaundice 2- anorexia 3- fatigue 4- nausea/vomiting 5- abdominal pain

what is the clinical outcome if acute HCV infection goes without treatment (1)

1- 75-85% of acute infections will become chronic and can lead to cirrhosis, liver failure, hepatocellular carcinoma

what does HCV RNA indicate as a test (1)

1- measure of viral load and detectable only during active infection (not with past/resolved infections)

what does anti-HCV antibody indicate as a test (1)

1- is positive in current and past infections, including resolved infections

is there a treatment for hep C (1) and how does it compare to older treatments (1)

1- yes - direct-acting antiviral (DAA) tablets achieve permanent cure in > 90% of cases 2- fewer side-effects and shorter treatment regimens with DAAs than interferon (defunct) and ribavirin

HCV case management: what do you do for case investigation (3)

1- determine risk factors 2- determine possible source of infection 3- test anti-HCV-positive people for HCV RNA

HCV case management: can a HCV case (past or present) donate blood

1- NO do not donate blood or blood products

HCV case management: what vaccines should HCV cases receive (1)

1- publicly-funded Hep A and B vaccines for those with chronic liver disease including those with hepatitis (consult provincial immunization manual)

HCV contact mgmt: when is contact notification recommended (1)

1- notify contacts for cases whose HCV RNA status is positive or unknown, and contacts meet defined criteria (see groups)

HCV contact mgmt: what are groups who would be considered contacts (3)

1- those who have shared drug equipment with a case 2- those who have shared personal-use items with a case (e.g. razor, toothbrush) 3- sexual partners with high-risk sexual behaviour, blood-to-blood contact, long term partners

HCV contact mgmt: what is the timeframe to conduct contact follow-up (1)

1- outer limit to identify contacts is onset of risky behaviour, or previous negative antibody result (whichever is more recent)

screening for hep C (hot topic) - what is the guidance from CASL (Canadian association for the study of the liver) (1)

1- 2018 guideline recommends targeted screening in those at high risk, and also those born from 1945 to 1975

screening for hep C (hot topic) - what is the guidance from CTFPHC (Canadian task force) (1)

1- 2017 guideline recommends against screening for HCV in adults who are not at elevated risk